Practical impact of unannounced audits for combination product makers in the EU
This article was originally published in SRA
While there is much speculation as to how the new EU regulatory structure for high-risk devices, including device/drug combinations, will pan out, and how soon the new Medical Device Regulation will take effect, there is a more urgent matter for companies to attend: the tighter regulatory environment that will result from the new European Commission documents on the designation and oversight of notified bodies, and on audits by notified bodies1,2.
You may also be interested in...
While the UK is moving forward quickly to provide COVID-19 antibody self-testing, the Belgian government considers the tests are not sufficiently accurate to be used in the pandemic.
Following hot on the heels of its Rapidly Manufactured Ventilator Specification document, the UK’s regulator has issued another speedy regulatory permit for fast production of respiratory assist devices.
The UK is taking measures to increase its ventilator stock from 8,000 to some 30,000, but it will take time to make them available. Many are asking whether the government really rejected EU help, which could have brought relief sooner, because of Brexit.